The mean percentage of body weight loss at 72 weeks was 15.0% at the lowest dose, and 20.9% in the highest dose cohort (compared to 3.1% in placebo) (NCT04184622)
Plaintiffs pursuing such claims now face two choices: they can either file a new MDL focusing solely on blood clot injuries or litigate the cases separately in state or federal courts nationwide
GLP-1s: The Second Serving Revisiting our GLP-1 Basket In case you missed it, our new portal allowing real-time tracking and performance on every thematic basket we cover and our model portfolio recently went live at citrindex.com Introduction Two years ago, CitriniResearchs third-ever thematic primer Upgrading from Overweight made a host of bold claims about the new class of weight loss drugs, GLP-1s
Four months into Zepbound (a popular GLP-1 medicine), however, something changed
For instance, in December 2023, Lupin Limited, one of the global pharmaceutical companies, received tentative approval from the U.S